T-DM1 as a Treatment for Breast Cancer
Edith A. Perez, MD, discusses the antibody drug conjugate T-DM1 (trastuzumab emtansine; Kadcyla) as a treatment for patients with breast cancer.
Edith A. Perez, MD, professor of medicine, Mayo Clinic, discusses the antibody drug conjugate T-DM1 (trastuzumab emtansine; Kadcyla) as a treatment for patients with breast cancer.
Clinical Pearls:
- T-DM1 is a combination of trastuzumab and a chemotherapy agent all in one compound
- Once the drug is injected into the vein, T-DM1 finds the cells that overexpress HER2 and then places the chemotherapy inside the tumor cell
- The results of the MARIANNE trial, which will examine T-DM1 plus pertuzumab, T-DM1 with pertuzumab or placebo, and trastuzumab plus a taxane (docetaxel or paclitaxel) in patients with metastatic breast cancer, could be practice changing
Sequencing Sacituzumab and Other Drugs in HR+, HER2- Breast Cancer
May 16th 2024During a Case-Based Roundtable® event, Stephanie L. Graff, MD, discussed multiple later-line treatment options in hormone receptor–positive breast cancer with participants in the first article of a 2-part series.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
